Cartesian Therapeutics (RNAC) Debt to Equity (2016 - 2023)
Historic Debt to Equity for Cartesian Therapeutics (RNAC) over the last 9 years, with Q4 2023 value amounting to -$0.06.
- Cartesian Therapeutics' Debt to Equity fell 12297.55% to -$0.06 in Q4 2023 from the same period last year, while for Dec 2023 it was -$0.06, marking a year-over-year decrease of 12297.55%. This contributed to the annual value of -$0.06 for FY2023, which is 12297.55% down from last year.
- Cartesian Therapeutics' Debt to Equity amounted to -$0.06 in Q4 2023, which was down 12297.55% from $0.37 recorded in Q2 2023.
- In the past 5 years, Cartesian Therapeutics' Debt to Equity registered a high of $384.79 during Q2 2019, and its lowest value of -$5.97 during Q2 2021.
- For the 5-year period, Cartesian Therapeutics' Debt to Equity averaged around $19.53, with its median value being $0.28 (2022).
- In the last 5 years, Cartesian Therapeutics' Debt to Equity skyrocketed by 4391127.19% in 2019 and then crashed by 42566.54% in 2021.
- Cartesian Therapeutics' Debt to Equity (Quarter) stood at $2.25 in 2019, then plummeted by 161.16% to -$1.38 in 2020, then soared by 182.66% to $1.14 in 2021, then plummeted by 75.41% to $0.28 in 2022, then crashed by 122.98% to -$0.06 in 2023.
- Its Debt to Equity was -$0.06 in Q4 2023, compared to $0.37 in Q2 2023 and $0.35 in Q1 2023.